Ruane, Cunniff & Goldfarb L.P. Atai Life Sciences N.V. Transaction History
Ruane, Cunniff & Goldfarb L.P.
- $4.74 Billion
- Q1 2025
A detailed history of Ruane, Cunniff & Goldfarb L.P. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Ruane, Cunniff & Goldfarb L.P. holds 42,112 shares of ATAI stock, worth $104,437. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,112
Previous 42,112
-0.0%
Holding current value
$104,437
Previous $56,000
1.79%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ATAI
# of Institutions
98Shares Held
23.7MCall Options Held
351KPut Options Held
170K-
Ubs Group Ag5.54MShares$13.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.29MShares$8.17 Million0.0% of portfolio
-
Pale Fire Capital Se Prague, 2N2.59MShares$6.43 Million0.42% of portfolio
-
Davidson Kempner Capital Management LP New York, NY1.41MShares$3.51 Million0.07% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$3.24 Million0.0% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $411M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...